Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Fetrastobart Vedotin

Antibody-drug conjugate · Cytotoxic, directed at PD-L1 (CD274) · developed by Pfizer

Phase 3 Most advanced trial
PFE Developer

What is Fetrastobart Vedotin?

Fetrastobart vedotin is an antibody-drug conjugate in which an antibody against PD-L1 is linked to the cytotoxic agent MMAE through a protease-cleavable linker. After binding PD-L1 on tumor cells and internalization, MMAE is released, inhibits microtubule polymerization and induces cell cycle arrest and apoptosis. It is being studied in non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PF-08046054
Drug type
Antibody-drug conjugate
Targets
PD-L1 (CD274), tubulin (secondary target)
Mechanism
Cytotoxic, directed at PD-L1 (CD274)
Pathways
microtubule polymerization inhibition, G2/M cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
Pfizer (PFE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
MJ6ZDB8P4Z

Conditions studied

Non-small Cell CarcinomaNon-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Carcinoma

Other drugs acting on CD274

More from Pfizer

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Fetrastobart Vedotin

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.